Interestingly, this was not observed in the PRAD cohort (Supplementary Fig. s2a), where only samples with RB1 mutation, independently of the TP53 status, showed increased CDC7 expression to that observed in the double wild type tumors (Supplementary Fig. s2a). Here, TP53 is linked to prostate adenocarcinoma.